Skip to main content
. 2017 Aug 18;8(49):85599–85611. doi: 10.18632/oncotarget.20343

Table 3. Subsequent therapies of 177 RHCC patients according to AFP change.

Therapy Group A (n= 51) Group B (n= 43) Group C(n=83) P value
Any/none 16/35 14/29 28/55 0.960
RFA
 Yes/no
3/48 3/40 5/78 0.972
Resection
 Yes/no
4/47 5/38 7/76 0.788
Liver transplantation
 Yes/no
2/49 1/42 5/78 0.620
chemo-, radiotherapy
 Yes/no
2/49 1/42 2/81 0.854
Sorafenib
 Yes/no
5/46 4/39 9/74 0.959